Skip to content

Metabolomic Diagnostics appoints Dr. Ana Panigassi as Head of Clinical Affairs

Metabolomic Diagnostics, the Ireland based, deep tech medical diagnostics company, today announced the appointment of Dr. Ana Panigassi to the position of Head of Clinical Affairs at Metabolomic Diagnostics.

Metabolomic Diagnostics is globally recognized for its expertise in creating novel biomarker based diagnostic solutions for complex diseases.

Dr. Panigassi specialises in Obstetrics and Gynaecology and Maternal-Fetal Medicine. She has several years of clinical experience as a consultant physician along with a strong academic background. She has tutored all levels of medical students and residents and is also a published author. Her most significant research was carried out with the First Trimester Screening Group at Unifesp (São Paulo, Brazil), of which she is one of the founding members.

Ana moved to Ireland in 2015 and started a deep dive into Innovation in Healthcare helping teams to establish innovative start-ups.  “I am really looking forward to working with the Metabolomic Diagnostic’s team to deliver this innovative preeclampsia screening product to the global market place. The team are developing a disruptive solution and I am excited to be involved” says Ana

Ana is a great addition to our team and gives us the direct perspective of a practicing obstetrician who has dealt with the devastating consequences of preeclampsia” says Robin Tuytten CEO “With Ana’s insight we will be able to further tailor our offering to directly meet obstetricians needs in managing pregnancy complications like preeclampsia and saving lives of mothers and babies. We are very excited to welcome Ana and look forward to working closely with her.”

Metabolomic Diagnostic’s high-performance R&D team has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory. This pipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.

For further information contact:

Posted in